Published in Cancer Weekly, December 11th, 2001
The data reveal that doctors can offer patients, who are not suitable for breast conserving surgery, an effective, tolerable, licensed therapy proven to shrink tumors. Breast conserving surgery after treatment with Femara may be a viable option in these patients, where previously a mastectomy would have been carried out.
Trialist, Professor Oleg Eremin, consultant breast surgeon at Lincoln...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.